CP and infection: Recent data suggest a benefit of CP therapy, in conjunction with antiviral and immunomodulators, in treating moderate to severe COVID-1943,44 but also show that CP infusion early during the course of infection may be more beneficial as antibody responses are generated within 2 weeks of symptom onset45.